Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Vraciu

Child & Adolescent Psychiatry Canton, OH Doctor of Osteopathy

NPI 1962638239 CMS profile 1073974

4773 Higbee Ave Nw, Canton, OH 44718

Open in the dashboard

General payments

$11,409

709 records reported · program years 2019–2025

Research payments

$125

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Vraciu of Canton, OH is reported in the CMS Open Payments database as having received $11,409 across 709 general payments and $125 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,016 119
2024 General $2,137 104
2023 General $1,760 98
2022 General $1,611 100
2021 General $1,807 135
2020 General $1,216 92
2019 General $864 61
2019 Research $125 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Vraciu
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to John Vraciu were reported at $2,016. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year John Vraciu Child & Adolescent Psychiatry median Middle half National median
2019 $864 $129 $42–$419 $163
2020 $1,216 $81 $28–$226 $114
2021 $1,807 $115 $31–$326 $132
2022 $1,611 $124 $40–$382 $149
2023 $1,760 $130 $45–$420 $160
2024 $2,137 $141 $42–$490 $164
2025 $2,016 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,173 100 payments
  2. Alkermes, Inc. $1,066 57 payments
  3. Corium, Inc. $1,049 62 payments
  4. Tris Pharma Inc $963 82 payments
  5. Otsuka America Pharmaceutical, Inc. $907 48 payments
  6. Ironshore Pharmaceuticals Inc. $825 51 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $771 49 payments
  8. Supernus Pharmaceuticals, Inc. $664 22 payments
  9. ITI, Inc. $642 30 payments
  10. Neos Therapeutics, LP $564 51 payments
  11. Other $2,784 157 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,348 703 payments
  2. Education $58 3 payments
  3. Gift $3 3 payments
Products named General payments · program years 2019–2025
  1. Azstarys $1,049 62 payments
  2. ARISTADA Cns $999 54 payments
  3. ARISTADA Cns $999 54 payments
  4. REXULTI $844 45 payments
  5. VRAYLAR $832 73 payments
  6. LYBALVI $793 40 payments
  7. ARISTADA Cns $791 43 payments
  8. ARISTADA Cns $791 43 payments
  9. TRINTELLIX $643 39 payments
  10. CAPLYTA $465 23 payments
  11. Other $7,686 484 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Indivior Inc. $125 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

392

Median for Psychiatry: 574

Drug cost

$22,480

Median for Psychiatry: $27,624

Branded share of claims

40.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 78 $10,686
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 15 $6,062
Clozapine Generic 18 $2,393
Buprenorphine Hcl Generic 41 $1,419
Bupropion Xl Bupropion Hcl Brand 35 $501
Buspirone Hcl Generic 15 $232
Gabapentin Generic 19 $228
Lamotrigine Generic 14 $198
Clonazepam Generic 50 $144
Venlafaxine Hcl Er Venlafaxine Hcl Brand 13 $118

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $340
$340 — —
Azstarys
  • Corium, Inc. $332
$332 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $244
$244 — —
VRAYLAR
  • AbbVie, Inc. $228
$228 — —
REXULTI
  • Lundbeck LLC $85
  • Otsuka America Pharmaceutical, Inc. $74
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

710 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record